BE905200A - Procede de preparation d'une forme granulaire a liberation retardee d'un principe actif et forme granulaire obtenue. - Google Patents

Procede de preparation d'une forme granulaire a liberation retardee d'un principe actif et forme granulaire obtenue.

Info

Publication number
BE905200A
BE905200A BE0/216995A BE216995A BE905200A BE 905200 A BE905200 A BE 905200A BE 0/216995 A BE0/216995 A BE 0/216995A BE 216995 A BE216995 A BE 216995A BE 905200 A BE905200 A BE 905200A
Authority
BE
Belgium
Prior art keywords
granular form
preparation
delayed
active ingredient
dispersible
Prior art date
Application number
BE0/216995A
Other languages
English (en)
Original Assignee
Zyma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zyma Sa filed Critical Zyma Sa
Publication of BE905200A publication Critical patent/BE905200A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procédé de préparation d'une forme granulaire à libération retardée d'une substance pharmaceutiquement active, ou de leurs mélanges, où l'on enrobe une substance pharmaceutiquement active granulée ou cristalline, ou leurs mélanges, avec un mélange de matières enrobantes constitué essentiellement d'un mélange homogène d'un (méthyl+éthyl) ester de l'acide poly(H + méth)-acrylique qui est insoluble mais dispersable dans l'eau et d'une éthyl-cellulose qui est insoluble mais dispersable dans l'eau dans un rapport pondéral de 20:1 à 1:5, caractérisé en ce qu'on chauffe les granules enrobés pendant au moins 5 minutes à des températures élevées allant de 50 degrés à 12 degrés C ainsi que la forme granulaire obtenue.
BE0/216995A 1985-07-31 1986-07-30 Procede de preparation d'une forme granulaire a liberation retardee d'un principe actif et forme granulaire obtenue. BE905200A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858519310A GB8519310D0 (en) 1985-07-31 1985-07-31 Granular active substances

Publications (1)

Publication Number Publication Date
BE905200A true BE905200A (fr) 1987-01-30

Family

ID=10583125

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/216995A BE905200A (fr) 1985-07-31 1986-07-30 Procede de preparation d'une forme granulaire a liberation retardee d'un principe actif et forme granulaire obtenue.

Country Status (23)

Country Link
US (1) US4728513A (fr)
JP (1) JPS6229514A (fr)
AT (1) AT392901B (fr)
AU (1) AU596804B2 (fr)
BE (1) BE905200A (fr)
CH (1) CH670566A5 (fr)
DE (1) DE3625458A1 (fr)
DK (1) DK361786A (fr)
ES (1) ES2000577A6 (fr)
FI (1) FI863074A7 (fr)
FR (1) FR2585570B1 (fr)
GB (2) GB8519310D0 (fr)
GR (1) GR862017B (fr)
HU (1) HU196304B (fr)
IL (1) IL79537A (fr)
IT (1) IT1195985B (fr)
LU (1) LU86523A1 (fr)
NL (1) NL8601961A (fr)
NZ (1) NZ217028A (fr)
PH (1) PH23531A (fr)
PT (1) PT83093B (fr)
SE (1) SE8603247L (fr)
ZA (1) ZA865691B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4726952A (en) * 1983-08-11 1988-02-23 Mission Pharmacal Slow-release sodium fluoride tablet, method of making, and method of treatment of osteoporosis
JPH0830005B2 (ja) * 1985-09-25 1996-03-27 ゲルゲリイ、ゲルハルト 崩壊性錠剤とその製造方法
CH669523A5 (fr) * 1986-06-25 1989-03-31 Mepha Ag
US4859467A (en) * 1986-09-25 1989-08-22 Colgate-Palmotive Company Sustained release fluoride composition
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
DE3712095A1 (de) * 1987-04-10 1988-10-20 Lentia Gmbh Bindemittelfreies granulat mit verzoegerter wirkstoffabgabe
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
IT1227899B (it) * 1988-12-23 1991-05-14 Poli Ind Chimica Spa Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni
IE69270B1 (en) * 1989-01-03 1996-08-21 Sterling Winthrop Inc Controlled-release low-dose aspirin
US4970081A (en) * 1989-01-03 1990-11-13 Sterling Drug Inc. Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US5013728A (en) * 1990-05-04 1991-05-07 Colgate - Palmolive Company Composition for treating osteoporosis and hormonal imbalance
US5153005A (en) * 1990-12-11 1992-10-06 Colgate-Palmolive Company Composition and method for preventing fluorosis
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
FI101039B (fi) * 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
SG52402A1 (en) * 1992-12-22 1998-09-28 Univ Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5674529A (en) * 1995-06-06 1997-10-07 Church & Dwight Co., Inc. Alkalinizing potassium salt controlled release preparations
FR2760190B1 (fr) * 1997-02-28 1999-04-09 Adir Composition pharmaceutique pour la liberation programmee de dexfenfluramine
WO1999001111A1 (fr) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Formulations de tramadol stabilisees a liberation prolongee
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
FR2785539B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Particules enrobees d'ibuprofene cristallin granule
DE19928312A1 (de) * 1999-06-16 2000-12-21 Schering Ag Arzneimittelzubereitung mit verzögerter Wirkstoffabgabe
DE60036874T2 (de) 1999-09-02 2008-06-26 Nostrum Pharmaceuticals Inc. Pellet formulierung mit gesteuerter freisetzung
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2283829A1 (fr) 2000-10-30 2011-02-16 Euro-Celtique S.A. Formulations d'hydrocodone à liberation lente
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
DE10152469A1 (de) * 2001-10-24 2003-06-26 Gruenenthal Gmbh 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US7410965B2 (en) * 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
US20050100577A1 (en) * 2003-11-10 2005-05-12 Parker Theodore L. Expandable medical device with beneficial agent matrix formed by a multi solvent system
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US7611630B2 (en) * 2004-03-30 2009-11-03 Bend Research, Inc. Method and device for evaluation of pharmaceutical compositions
DE102004035938A1 (de) * 2004-07-23 2006-02-16 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen mit stabilem Wirkstofffreigabeprofil
JPWO2006059716A1 (ja) * 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
EP2275088B2 (fr) * 2005-02-25 2018-09-26 Takeda Pharmaceutical Company Limited Procédé de fabrication de granulés
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
DE102006051020A1 (de) * 2006-10-26 2008-04-30 Evonik Röhm Gmbh Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
WO2008135852A2 (fr) * 2007-05-03 2008-11-13 Pfizer Products Inc. Compositions pharmaceutiques comprenant des nanoparticules et de la caséine
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
EP2162120B1 (fr) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticules comportant un polymère cellulosique non ionisable et un copolymère bloc amphiphile non ionisable
WO2008149230A2 (fr) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticules comprenant un médicament, un polymère cellulosique non ionisable et du tocophéryl polyéthylène glycol succinate
EP2178518A2 (fr) * 2007-07-13 2010-04-28 Bend Research, Inc Nanoparticules comprenant des polymères cellulosiques ionisables faiblement solubles dans l'eau
US8765187B2 (en) * 2007-07-17 2014-07-01 Asahi Kasei Chemicals Corporation Aqueous composition
EP2240162A4 (fr) * 2007-12-06 2013-10-09 Bend Res Inc Nanoparticules comprenant un polymère non ionisable et un copolymère de méthacrylate fonctionnalisé par amine
EP2231169B1 (fr) * 2007-12-06 2016-05-04 Bend Research, Inc. Compositions pharmaceutiques comprenant des nanoparticules et une matière de remise en suspension
CN103432093B (zh) * 2013-08-31 2015-03-25 西南大学 甲磺酸普立地诺骨架缓释片及其制备方法
CA2936741C (fr) 2014-10-31 2018-11-06 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US904848A (en) * 1908-05-27 1908-11-24 William W Devore Artificial whirlpool.
AT64577B (de) * 1913-04-28 1914-04-25 Carl Georg Rodeck Volksbelustigungsvorrichtung mit sich drehenden Plattformen.
US1689138A (en) * 1927-10-15 1928-10-23 Playground & Gymnasium Equipme Bathers' inclined rotary water platform
NL280825A (fr) * 1962-07-11
DE2010110A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrokapseln mit Hilfe von synthetischen Koazervaten
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
JPS52139715A (en) * 1976-05-14 1977-11-21 Nippon Kayaku Co Ltd Coated granules of alkali polyacrylate
EP0052075A1 (fr) * 1980-11-12 1982-05-19 Ciba-Geigy Ag Granule pharmaceutique à action retardée
JPS5867616A (ja) * 1981-10-15 1983-04-22 Tanabe Seiyaku Co Ltd 腸溶性マイクロカプセル
US4543886A (en) * 1983-03-09 1985-10-01 Intamin Inc. Amusement ride including a rotating loading terminal
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
CH666405A5 (de) * 1985-06-24 1988-07-29 Ciba Geigy Ag Feste, haltbare darreichungsformen mit elastischem filmueberzug.
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet

Also Published As

Publication number Publication date
JPS6229514A (ja) 1987-02-07
IL79537A0 (en) 1986-10-31
GB2178313A (en) 1987-02-11
DK361786D0 (da) 1986-07-30
IT1195985B (it) 1988-11-03
HUT41630A (en) 1987-05-28
HU196304B (en) 1988-11-28
NL8601961A (nl) 1987-02-16
SE8603247D0 (sv) 1986-07-29
PT83093B (pt) 1989-01-30
CH670566A5 (fr) 1989-06-30
ATA205686A (de) 1990-12-15
IT8648323A0 (it) 1986-07-29
LU86523A1 (fr) 1987-02-04
AU596804B2 (en) 1990-05-17
FR2585570A1 (fr) 1987-02-06
FI863074L (fi) 1987-02-01
DK361786A (da) 1987-02-01
GR862017B (en) 1986-12-23
NZ217028A (en) 1989-08-29
PH23531A (en) 1989-08-25
IL79537A (en) 1991-01-31
SE8603247L (sv) 1987-02-01
ZA865691B (en) 1987-03-25
FI863074A7 (fi) 1987-02-01
FR2585570B1 (fr) 1990-03-23
AU6068586A (en) 1987-02-05
AT392901B (de) 1991-07-10
GB8519310D0 (en) 1985-09-04
FI863074A0 (fi) 1986-07-28
US4728513A (en) 1988-03-01
PT83093A (en) 1986-08-01
GB2178313B (en) 1989-08-23
ES2000577A6 (es) 1988-03-01
GB8618153D0 (en) 1986-09-03
DE3625458A1 (de) 1987-02-12

Similar Documents

Publication Publication Date Title
SE8603247L (sv) Granulerad form med fordrojd frigoring av farmaceutiskt aktiva substanser
ES8800041A1 (es) Un procedimiento para la produccion de una composicion farmaceutica de liberacion controlada de unidades individuales
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
CA2127352A1 (fr) Preparation pharmaceutique sous la forme d'un comprime effervescent et/ou se desintegrant ou de granules a dissolution instantanee et procede d'obtention
BE901007A (fr) Comprimes pharmaceutiques a liberation etalee et procede pour les preparer.
NO860332L (no) Fremgangsmaate for fremstilling av terapeutisk aktive alfa-(2-okso-2,4,5,6,7,7a-heksahydro-tieno(3,2-c)-5-pyridyl)-fenyl-eddiksyre-derivater.
IE873213L (en) Galenical Formulation
CA2091370A1 (fr) Comprime, granule et pellets en substances actives a teneur elevee pour preparations pharmaceutiques solides tres concentrees
FI893403A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,4-dihydro-4-okso-3-kinoliinikarboksyylihappojohdannaisten ja niiden additiotuotteiden veden, happojen ja emästen kanssa, valmistamiseksi
EP0068450A3 (en) Pharmaceutical forms for oral administration
EP0107209A1 (fr) Préparation contenant du sucralfate
US4562061A (en) Pharmaceutical preparation
HK60192A (en) Drug particles having constant release
HK126193A (en) Drug particles having constant release
HU896803D0 (en) Antiparasitic, insecticide, acaricide and nematicide compositions comprising fluor derivatives of 3-ethinyl-2,2-dimethyl cyclopropane carboxylic acid as active ingredient and process for preparation thereof
FR2515653B1 (fr) Procede de preparation d'esters d'acides hydroxyimino apovincaminiques, esters ainsi obtenus, et compositions pharmaceutiques preparees avec ces esters
ZA882415B (en) Binder-free granules with delayed release of the active compound
CA2015632A1 (fr) Solutions stables d'un analogue de la rebeccamycine et preparations realisees a partir d'elles
JPS56148291A (en) Stabilizing agent for enzyme
OA07540A (fr) Nouveaux dérivés de l'acide cyclopropane carboxylique, leur préparation, leur application à la lutte contre les parasites et les compositions les renfermant.
JPS5668672A (en) Novel 2-acetoxybenzamide derviative, its preparation, and pharmaceutical containing said derviative as effective component
ATE110564T1 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren.
Yeh et al. Antagonistic effect of two forms of clofibrate on mitochondrial oxidation of succinate
Horton et al. Behavioural effects of allylglycine (2-amino-4-pentenoic acid) and 2-keto-4-pentenoic acid following focal injection into the rat cerebellum and caudate nucleus [proceedings]
FR2392988A1 (fr) Nouveaux esters doues notamment d'activite pharmacologique, procedes de preparation de tels esters et compositions pharmaceutiques les renfermant

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: ZYMA S.A.

Effective date: 19910731